DrugPatentWatch Database Preview
SLYND Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Slynd patents expire, and when can generic versions of Slynd launch?
Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. There are two patents protecting this drug.
This drug has thirty-six patent family members in twenty-three countries.
The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the drospirenone profile page.
US ANDA Litigation and Generic Entry Outlook for Slynd
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 23, 2022. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for SLYND
| International Patents: | 36 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 63 |
| Patent Applications: | 1,019 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SLYND |
| DailyMed Link: | SLYND at DailyMed |
Generic Entry Opportunity Date for SLYND
Generic Entry Date for SLYND*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for SLYND
| Drug Class | Progestin |
US Patents and Regulatory Information for SLYND
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SLYND
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | 112012033391 | Start Trial |
| Mexico | 2019004393 | Start Trial |
| Guatemala | 201200336B | Start Trial |
| New Zealand | 605176 | Start Trial |
| Lithuania | 2588114 | Start Trial |
| South Korea | 20170085604 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for SLYND
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1380301 | 2009C/007 | Belgium | Start Trial | PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811 |
| 0398460 | SPC/GB04/032 | United Kingdom | Start Trial | PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310 |
| 1214076 | C01214076/01 | Switzerland | Start Trial | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
| 0398460 | 04C0022 | France | Start Trial | PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
